IKS03 for Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new treatment called IKS03 for people with advanced B-cell Non-Hodgkin Lymphoma (a type of cancer that starts in white blood cells). IKS03 is an antibody-drug conjugate, meaning it's designed to specifically target cancer cells. You might be able to join if you are 18 or older and have certain types of B-cell Non-Hodgkin Lymphoma, including Diffuse Large B Cell Lymphoma or Follicular Lymphoma. The study aims to find the safest and most effective dose of IKS03 and see how well it shrinks tumors. The study plans to enroll 140 participants. The current status of the study is unclear.
- Study design
- This is a two-part study: first, a dose-escalation phase to find the right dose, and then a dose-expansion phase to further evaluate safety and effectiveness. It is an interventional study, meaning participants will receive the study drug.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure the recommended dose for expansion for up to 20 months and the objective response rate for up to 42 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
At a glance
Conditions
Where it's being run
13 sites across 8 statesStudy leadership
- Debra Wood, MD · STUDY_DIRECTOR · Iksuda Therapeutics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Recommended Phase 2 Dose (Part I)Up to 20 months
RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
- Objective Response Rate (Part II)up to 42 months
Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014)